生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | TMP195 effectively hinders the accumulation of CCL2 protein in the culture supernatants during the differentiation of monocyte-derived macrophages, while markedly enhancing the secretion of CCL1 protein by monocytes in comparison to the vehicle-treated group. This alteration in cytokine profile is confirmed by transcriptional profiling data from PHA-stimulated peripheral blood mononuclear cell (PBMC) experiments, where CCL2 is downregulated and CCL1 is upregulated following TMP195 treatment[1]. The mechanism of action of TMP195 involves its competition for the acetyllysine-binding site of class IIa HDACs, effectively preventing HDAC7 from binding to various side-chain modifications on a peptide backbone. Notably, this competitive inhibition does not affect the function of other acetyllysine reader proteins such as BRD4, where TMP195 shows no inhibitory activity at concentrations up to 50 μM[2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.19mL 0.44mL 0.22mL |
10.95mL 2.19mL 1.10mL |
21.91mL 4.38mL 2.19mL |
参考文献 |
---|